Boston Scientific (BSX) News Today

Capital International Sarl bought a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 66,823 shares of the medical equipment provider's sto

Boston Scientific (NYSE:BSX - Get Free Report) announced its quarterly earnings data on Wednesday. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The firm's revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 EPS.

Deutsche Bank Aktiengesellschaft increased their target price on Boston Scientific from $73.00 to $78.00 and gave the company a "hold" rating in a research note on Thursday.

Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price objective on shares of Boston Scientific in a research report on Thursday.

UniSuper Management Pty Ltd grew its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 178.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 33,732 shares of the medical equipment provider's stock after purchasing an add

Boston Scientific (NYSE:BSX) Sees Large Volume Increase

Boston Scientific (NYSE:BSX) updated its FY 2024 earnings guidance. The company provided EPS guidance of 2.380-2.420 for the period, compared to the consensus estimate of 2.330. The company also issued revenue guidance of $16.2 billionillion-$16.3 billionillion, compared to the consensus estimate of $16.0 billionillion.

Seven Eight Capital LP lowered its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 88.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,555 shares of the medical equipment provider's stock after selling 87,581 shares du

Boston Scientific (NYSE:BSX) Hits New 52-Week High at $79.08

Acadian Asset Management LLC raised its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 89.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 93,258 shares of the medical equipment provider's stock after purchasing an additional

Boston Scientific Co. (NYSE:BSX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-one brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has i

TIAA Trust National Association decreased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 14.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 241,188 shares of the medical equi

Mizuho Markets Americas LLC cut its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 18.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 458,000 shares of the medical equipment provider's

Lord Abbett & CO. LLC lowered its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 95.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,652 shares of the medical equipment provider's stock after

Boston Scientific Co. (NYSE:BSX - Get Free Report) saw some unusual options trading activity on Friday. Investors bought 8,128 put options on the company. This is an increase of 14% compared to the average volume of 7,144 put options.

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 20.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,758,963 shares of the medical equip

BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 10.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,021,803 shares of the